Evidence map›Paper›PMID 33686612›Full record

ArticleDrugs - real world outcomes2021

Visualization of Kinase Inhibition-Related Adverse Events Using the Japanese Adverse Drug Event Report Database.

Takahito Mizuno, Takamasa Sakai, Kouichi Tanabe, Takumi Umemura, Nobuyuki Goto, Fumiko Ohtsu

Open access · goldAbstract read
In one paragraph

Article in Drugs - real world outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Takahito MizunoDepartment of Pharmacy, Tosei General Hospital, 160-Nishioiwake-cho, Seto, Aichi, 489-8642, Japan. g0773259@ccalumni.meijo-u.ac.jp.ORCID http://orcid.org/0000-0003-0891-5873
Takamasa SakaiFaculty of Pharmacy, Meijo University, Aichi, Japan.
Kouichi TanabeFaculty of Pharmacy, Meijo University, Aichi, Japan.
Takumi UmemuraDepartment of Pharmacy, Tosei General Hospital, 160-Nishioiwake-cho, Seto, Aichi, 489-8642, Japan.
Nobuyuki GotoDepartment of Pharmacy, University of Fukui Hospital, Aichi, Japan.
Fumiko OhtsuFaculty of Pharmacy, Meijo University, Aichi, Japan.
Meijo University · JPTosei General Hospital · JPUniversity of Fukui Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSmall molecule tyrosine kinase inhibitors (TKIs) inhibit not only the target kinase but also various kinases as off-target inhibitors not mentioned in the package insert. However, there are no reports that comprehensively examine the relationship between adverse events and kinase affinity.

objectiveIn this study, we combined basic data and clinical data to visualize the relationship between kinase affinity and adverse events, which will be useful for the management of adverse events in clinical practice.

methodsWe targeted TKIs that have been used domestically and for which the dissociation constant was obtained as reported by Davis et al. Adverse event data recorded in the Japanese Adverse Drug Event Report (JADER) database provided by the Pharmaceuticals and Medical Devices Agency between April 2004 and January 2018 were used. We calculated the reporting rates of the Standardized MedDRA Queries (SMQ) for the adverse events of interest and visualized the correlation coefficients with kinase affinity. We used the adverse events associated with VEGFR2 and EGFR to assess their validity.

resultsWe found a correlation among known kinase-related adverse events, suggesting that the methodology may be used as a signal detection method to generate hypotheses for clinical and basic research.

conclusionOur comprehensive analysis of the kinase affinity of TKIs in this study, which was based on basic TKI kinase affinity data and the clinical data of the reporting rates, suggested that our comprehensive analysis method is useful for generating hypotheses about possible causal relationships between pharmacological effects and adverse events.

Identifiers

PMID33686612
PMCPMC8128962
OpenAlexW3135139552

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.